| Literature DB >> 28197305 |
David B Smithrud1, Lucas Powers1, Jennifer Lunn1, Scott Abernathy1, Michael Peschka1, Shuk-Mei Ho2, Pheruza Tarapore3.
Abstract
New therapies are needed to eradicate androgen resistant, prostate cancer. Prostate cancer usually metastasizes to bone where the concentration of calcium is high, making Ca2+ a promising toxin. Ionophores can deliver metal cations into cells, but are currently too toxic for human use. We synthesized a new rotaxane (CEHR2) that contains a benzyl 15-crown-5 ether as a blocking group to efficiently bind Ca2+. CEHR2 transfers Ca2+ from an aqueous solution into CHCl3 to greater extent than alkali metal cations and Mg2+. It also transfers Ca2+ to a greater extent than CEHR1, which is a rotaxane with an 18-crown-6 ether as a blocking group. CEHR2 was more toxic against the prostate cancer cell lines PC-3, 22Rv1, and C4-2 than CEHR1. This project demonstrates that crown ether rotaxanes can be designed to bind a targeted metal cation, and this selective cation association can result in enhanced toxicity.Entities:
Keywords: Prostate cancer; calcium; crown ethers; rotaxanes
Year: 2017 PMID: 28197305 PMCID: PMC5304289 DOI: 10.1021/acsmedchemlett.6b00347
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345